Covidien

The medical devices giant that is Covidien, shows its still on the acquisition trail with the announcement that it is to spend $300M buying Israeli respiratory monitoring company Oridion.

Another Covidien Acquisition, this time in its Airway and Ventilation Business, with announced purchase of Newport Medical Inc.

Covidien in the news again, this time with UK recall of LigaSure Dolphin Tip Sealer for fear of loose pins in the handle.

Covidien is back in the news this week with its announcement of the acquisition of Israeli pulmonology company superDimension Ltd.

FDA has now released summary information relating to last week’s newly US-cleared Everflex peripheral vascular stent from Covidien.

Covidien showcased its new iterations of trocar and tissue sealer at SAGES.

Covidien’s past acquisitions keep coming up trumps. EV3’s Everflex™ device has now been cleared for US marketing by FDA, bringing a useful new long stent option to peripheral vascular surgeons.

With a certain inevitability following rave reviews in its pivotal clinical study, Covidien’s revascularisation device for removing clots from occluded vessels in stroke patients has now gained FDA 510(k) clearance.

It’s only a month, but when people have died because of a medical device technology being found wanting, shouldn’t the UK’s competent authority have acted sooner?

Covidien commits itself to emerging markets by putting money where its mouth is with the opening of an R&D facility in Hyderabad.

Covidien’s stent-like clot retrieval device, SOLITAIRE FR, worked well enough in this randomised study to persuade the safety monitoring committee to end the trial early.

Covidien’s Solitaire FR device has been accepted into US stroke trial on an investigational basis. Company financials look strong and sounds bullish about the forthcoming tax levy.

Covidien’s Everflex system, designed to treat long vascular lesions with a single stent, is the subject of an extensive clinical study, interim results of which have been released. The stent is already approved for use in Europe.

Covidien has reinforced implementation of its voluntary recall of BIS bilateral Sensors, undertaken last November, with a reminder in the form of an update, that use of affected iterations of the product could result in what the company refers to as inaccurate calucation and presentation of key data.

Covidien has today announced that it is conducting a voluntary recall of all production lots for the Duet TRS™ Universal Straight and Articulating Single Use Loading Units, with respect to the use of this product family in the thoracic cavity.

Covidien extends the functionality of its Nellcor respiratory monitoring platform with CE Mark approval for its Nellcor™ Respiration Rate Version 1.0 Software and the Adult Respiration Rate Sensor.